![]() |
|
|
Departments of Medical Biochemistry and Biophysics (Y.H., M.O., I.J., M.I.-S.) and Laboratory Sciences and Technology (Q.-Y.Y., M.-L.D.), Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden, Department of Medical Sciences, University of Torino, Novara, Italy (E.A.), and Department of Medicine, University of Turin, Turin, Italy (M.T., S.A.)
| |
Summary |
|---|
|
|
|---|
Ethanol-inducible CYP2E1 is an enzyme of major toxicological interest
because it metabolizes several precarcinogens, drugs, and solvents to
reactive metabolites. CYP2E1 has also been implicated in alcohol liver
disease because of its contribution to oxidative stress. Previously,
polymorphic alleles with mutations in introns and in the 5
-flanking
regulatory region have been described, and their presence has been
related to the incidence of alcohol liver disease and lung cancer. In
the present investigation, we investigated whether any functional
mutations are linked to the above-mentioned rare alleles and also
screened for mutations in the open reading frame using single-stranded
conformation polymorphism and genomic DNA from almost 200 individuals
belonging to either a Chinese, an Italian, or a Swedish population. Two
new CYP2E1 gene variants were found with functional
mutations: one (CYP2E1*2) in which a G1168A point
mutation in exon 2 caused an R76H amino acid substitution, and the
other (CYP2E1*3) in which a G10059A base substitution in
exon 8 yielded a V389I amino acid exchange. The corresponding CYP2E1
cDNAs were constructed, subcloned into the pCMV4 expression
vector, and expressed in COS-1 cells. The cellular levels of CYP2E1
mRNA, CYP2E1 protein, and rate of chlorzoxazone hydroxylation were
monitored. The CYP2E1*3 cDNA variant was indistinguishable from the
wild-type cDNA on all variables investigated, whereas CYP2E1*2 cDNA,
although yielding similar amounts of mRNA, only caused 37% of the
protein expression and 36% of the catalytic activity compared with the
wild-type cDNA. Complete screening by single-stranded conformation
polymorphism of the three populations studied revealed that these
variant alleles were rare. We conclude that the human
CYP2E1 gene is functionally surprisingly well conserved compared with other cytochrome P450 enzymes active in drug metabolism, which suggests an important endogenous function in humans.
| |
Introduction |
|---|
|
|
|---|
Ethanol-inducible CYP2E1 has received much attention because of the potentially important toxicological roles of this enzyme. The enzyme is localized mainly in the liver but is also expressed and induced in the brain after ethanol treatment or ischemia (1, 2) and furthermore is distributed in many other tissues (3). The physiological role of this enzyme seems to be connected mainly with the conversion of acetone to gluconeogenetic precursors. Among the more than 70 different substrates specifically metabolized by this enzyme are most organic solvents, paracetamol, and several precarcinogens such as dimethylnitrosamine and ethanol (3, 4). In addition, CYP2E1 causes oxidative stress, and the oxy radicals generated by this enzyme are able to initiate NADPH-dependent lipid peroxidation with the concomitant production of cytotoxic aldehydes. These have been implicated in ethanol-mediated hepatotoxicity (5). Thus, any functional polymorphism of this enzyme might be an important factor in determining the relative risk of alcohol-mediated hepatotoxicity, any form of cancer, or susceptibility for drug toxicity.
With respect to the metabolism of drugs used for clinical purposes, CYP2E1 can be considered to be among the six most important P450s, which also include CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Among the clinically important drug substrates for CYP2E1 are enflurane, halothane, isoniazid, chlorzoxazone, paracetamol, and theophylline (6). Because CYP2C9, CYP2C19, and CYP2D6 have been shown to exhibit functional polymorphisms (7), it might be assumed that similar inactivating mutations also would occur in the CYP2E1 gene and that their distribution might be of importance for the efficacy of drug treatment or for interindividual differences in toxicity exerted by paracetamol, for example. In line with this hypothesis, it has been demonstrated that there are important interindividual differences in the expression of human hepatic CYP2E1 (8, 9).
Analysis and characterization of polymorphisms in the CYP2E1
gene has hitherto involved mainly RFLP analysis using the restriction endonucleases DraI, TaqI, and RsaI.
The polymorphic sites localized in introns and in the 5
-flanking
region have been monitored in this way (10, 11). Molecular
epidemiological studies have been carried out to relate the occurrence
of these variant alleles, in particular, the DraI C allele,
which has a mutation in intron 6 (allele frequency: Caucasians 10%,
Asians 26%) and at
1019 bp (c1/c2) in the 5
-upstream region
[allele frequency: Caucasians 4%, Asians 20% (3)], to the incidence
of lung cancer, susceptibility for alcohol liver disease (10-14),
inducibility of the enzyme by ethanol (15), and in vivo
activity (15, 16). We evaluated whether these polymorphic sites are
associated with any functional mutations in the open reading frame and,
furthermore, examined to what extent the human CYP2E1 gene
as such exhibits allelic variations in the open reading frame. For this
purpose, we screened genomic DNA for mutations from two Caucasian and
one Asian population using SSCP. The results indicate that the human
CYP2E1 gene is highly conserved in these populations
compared with other human P450 genes with products active in the
metabolism of xenobiotics.
| |
Materials and Methods |
|---|
|
|
|---|
Isolation of genomic DNA. Blood samples were obtained from healthy Swedish and Chinese control subjects and Italian alcoholic cirrhosis patients as described in previous publications (17-19). Genomic DNA was isolated using a guanidinium-isothiocyanate method or using the phenol extraction method (20). The studies were approved by the ethics committee at Karolinska Institutet.
Construction of genomic libraries.
The genomic libraries
were made from subjects homozygous for the DraI C and
DraI D alleles, respectively. When isolated, the DraI C allele exhibited mutations determined by
RsaI and TaqI RFLP but was of the c1 genotype
with respect to the 5
-upstream polymorphic site at
1019 bp (21).
Genomic DNA was partially digested by the restriction enzyme
Sau3AI and ligated to a
EMBL3 vector. Positive plaques
were identified by hybridization with 32P-labeled human
CYP2E1 cDNA.
SSCP analysis. One microliter of genomic DNA (~0.5 µg/µl) was amplified using the primers listed in Table 1. The PCR was carried out with initial denaturation for 1.5 min at 94°, followed by 35 cycles, each involving denaturation at 94° for 1 min, annealing at 52° for 1 min, and extension at 72° for 1 min. Five microliters of the PCR products was digested by an appropriate restriction enzyme in a total volume of 35 µl to yield 100- to 200-bp fragments. Subsequently, 15 µl of loading buffer containing 95% formamide, 20 mM EDTA, bromphenol blue, and xylene cyanol FF was added. Just before loading, the samples were heated to 95° for 5 min. Conformation polymorphisms of single-stranded DNA fragments were then analyzed using nondenaturing 8.7% polyacrylamide gels with 10% glycerol in a Hoeffer (San Francisco, CA) standard vertical SE 500-slab gel unit. The gels were run in 2× Tris/borate/EDTA buffer (0.18 M Tris base, 0.18 M boric acid, and 0.004 M EDTA), at 4° for 4 hr at 270 V, and the DNA fragments were visualized by silver staining.
|
DNA sequencing.
DNA was amplified by PCR with primers, as
shown in Table 1. One of the primers was biotinylated, and the PCR
reaction was conducted as described above. Forty microliters of PCR
products was mixed with Dynabeads M-280 Streptavidin (Dynal AS; Oslo,
Norway), which was designed as a matrix for simple and efficient
separations of biotinylated compounds. DNA strands were separated with
0.1 M NaOH using the Dynal Magnetic Particle Concentrator.
Sequencing of DNA was carried out by the dideoxy chain-termination
method using Sequenase version 2.0 T7 DNA polymerase (United States
Biochemical, Cleveland, OH) and
-35S-labeled dATP
(Amersham, Buckinghamshire, UK).
Site-directed mutagenesis.
Mutant CYP2E1 cDNAs containing
the G1168A or G10059A (numbering based on genomic DNA) mutations were
generated with the USE mutagenesis kit (Pharmacia Biotech, Uppsala,
Sweden), using a human CYP2E1 wild-type cDNA subcloned into the
pBluescript KS+ vector (Stratagene, La Jolla, CA), and
mutagenic primers 5
-GCTCGCAGCACATGGTGGT-3
and
5
-GGCACAGTCATAGTGCCAA-3
, respectively. The three cDNAs
were subsequently subcloned into the pCMV4 expression vector
(22) using the restriction sites HindIII and
XbaI.
Expression of mutated cDNAs. COS-1 cells were transfected with the pCMV4 constructs as previously described (18). After incubation for 72 hr, the cells were harvested in 100 mM sodium phosphate buffer, pH 7.4.
Quantification of CYP2E1 mRNA and apoprotein levels. Total RNA was prepared from transfected cells using the TriPure Isolation Reagent (Boehringer Mannheim, Mannheim, Germany). Northern blot analysis was performed as previously described (23). Cells for Western blot and chlorzoxazone 6-hydroxylation analysis were sonicated for 20 × 1 sec and centrifuged at 10,000 × g for 10 min at 4°. Supernatant corresponding to 10 µg of protein was subjected to sodium dodecyl sulfate gel electrophoresis using 8.7% polyacrylamide gels, and the proteins were subsequently transferred to a Hybond C nitrocellulose filter (Amersham) and incubated with anti-rat CYP2E1 serum (24) and with horseradish-peroxidase-linked protein A (BioRad, Hercules, CA). The enhanced chemiluminescense method (Amersham) was used to visualize the proteins, and quantification was carried out using a personal densitometer (Molecular Dynamics, Sunnyvale, CA).
Chlorzoxazone 6-hydroxylation assay. Cell supernatant (10,000 × g) corresponding to 300 µg of protein was incubated at 37° in 100 mM sodium phosphate buffer, pH 7.4, with 1 mM chlorzoxazone, 1 mM NADPH, and 28 pmol of rat P450 reductase [purified as described by Ingelman-Sundberg and Glaumann (25)] in a total volume of 500 µl for 180 min. The addition of reductase makes CYP2E1 the rate-determining factor, because the endogenous reductase levels in the COS cells are small. The reaction was terminated by the addition of 50 µl of 43% orto-phosphoric acid, and 1 µg of acetaminophen was added as an internal standard. Extraction of samples with dichloromethane and analysis of the amount of 6-OH-chlorzoxazone formed was carried out with an high pressure liquid chromatography system using an electrochemical detector as described elsewhere (2). Linearity of the reaction for 180 min was established in all cases.
| |
Results |
|---|
|
|
|---|
Two genomic libraries were constructed from two Caucasian subjects
homozygous for the DraI C and DraI D haplotypes,
respectively. The C allele of the c1 genotype with respect to the
polymorphism at
1019 bp (26) was fully sequenced in its open reading
frame and in parts of the 3
- and 5
-flanking regions. Several
mutations compared with the DraI D allele (27) were seen in
the flanking regions (Fig. 1), among them an insertion
(guanine) at position
13 in the promoter region adjacent to the
TATA-box. Some mutations in the 3
-flanking region were in putative
motifs determining mRNA stability, such as polyadenylation signal (Fig.
1). Furthermore, many mutations were seen in areas sequenced in intron
6, as well as in the more remote 5
-upstream flanking regions. However,
no mutations were found in any of the exons.
|
To investigate any polymorphic alleles with functional mutations, SSCP analysis was carried out on all exons and exon-intron junctions using the genomic DNA of 198 subjects: 78 Swedish control subjects, 78 Chinese control subjects, and 42 Italian patients suffering from alcohol-induced liver cirrhosis. The exons were amplified by PCR using the primers listed in Table 1, and the products were digested by appropriate restriction endonucleases to yield 100- to 200-bp fragments. In two of the 78 Chinese subjects, the SSCP analysis revealed a mobility difference of the PCR products from exon 2 obtained after digestion with RsaI (Fig. 2A). Direct sequencing revealed a G1168A point mutation (Fig. 2B), which caused an R76H amino acid substitution (Fig. 2C). The mutation is localized at a polymorphic restriction HhaI site (GCGC to GCAC) (Fig. 2C), and the allele was designated CYP2E1*2.1
|
Using the same approach, we also found that 1 of the 42 Italian
alcoholic cirrhosis patients showed a unique pattern in the SSCP
analysis of exon 8 (Fig. 3A). Sequence analysis revealed a G10059A mutation (Fig. 3B), which caused a V389I amino acid substitution (Fig. 3C). This allele was designated
CYP2E1*3.1 Using SSCP and sequence analysis, we
identified a point mutation, G
35T, only 2 bp downstream
of the basal transcription element in the 5
-flanking region (data not
shown).
|
To evaluate the functional importance of the mutations in the CYP2E1*2 and CYP2E1*3 alleles, site-directed mutagenesis was used to introduce these mutations into the wild-type CYP2E1 cDNA. The cDNAs were inserted into the pCMV4 expression vector and subsequently expressed in COS-1 cells. For comparison, cells transfected with the vector alone were used as negative controls. The amount of CYP2E1 mRNA was detected by Northern blot, and the CYP2E1 apoprotein levels were quantified by Western blot. The CYP2E1-dependent catalytic activities were determined by measuring NADPH-dependent hydroxylation of chlorzoxazone in 10,000 × g supernatants of the transfected cells.
All constructs except the pCMV4 vector yielded CYP2E1 mRNA and immunodetectable CYP2E1 apoprotein. No major differences in mRNA levels were noticed in cells transfected with either of the three different cDNAs (Fig. 4, A and B). The level of CYP2E1 apoprotein in cells transfected with CYP2E1*2 cDNA was approximately 37% of that obtained in cells transfected with CYP2E1*1 cDNA (Fig. 4C). When 6-hydroxylation of chlorzoxazone was measured in the cell homogenates, a similar decrease was seen in activities as monitored on the protein level. By contrast, cells transfected with CYP2E1*3 cDNA had apoprotein levels and rates of chlorzoxazone 6-hydroxylation similar to that of cells transfected with CYP2E1*1 cDNA (Fig. 4D).
|
The presence of these mutations in the populations investigated was screened by SSCP. Two CYP2E1*2 alleles were found in the Chinese population and one CYP2E1*3 allele in the Italian population, whereas neither was present in the Swedish population studied (Table 2). This shows the high conservation of the open reading frame of the human CYP2E1 gene and indicates an important physiological function of this enzyme in vivo. No relationship between the distribution of these variant alleles and the previously described C/D and c1/c2 polymorphisms was found.
|
| |
Discussion |
|---|
|
|
|---|
Much interest has been focused on the relationship between
polymorphism of the human CYP2E1 gene as studied by RFLP and
the incidence of lung cancer as well as the occurrence of alcoholic liver disease. In particular, two polymorphic loci, one in intron 6 (DraI C/D) and one in the 5
-flanking upstream region
(c1/c2) have received much attention. To evaluate any relationship
between these polymorphic alleles and any functional mutations and,
furthermore, to investigate the occurrence of any mutations in the open
reading frame, conditions for SSCP analysis were worked out to include all the exons and intron-exon junctions. Screening of a total of 198 individuals revealed that the coding part of the gene is well conserved
among individuals and that only three alleles were found to cause amino
acid exchanges. One of them, which had the R76H substitution
(CYP2E1*2), caused less apoprotein levels and catalytic
activity in the expression system, whereas no effect was seen on the
mRNA level. The very similar decreases of both the protein and
catalytic activity of this CYP2E1 variant suggests that the mutation
does not affect the catalytic activity of the enzyme but that less
protein is formed, perhaps because of a decreased translation
efficiency or less stable protein. The expression system used does not,
however, allow us to extrapolate this finding to the human in
vivo situation. Our finding of a detrimental effect of the R76H
substitution has to be confirmed in vivo using phenotype analysis with the chlorzoxazone of humans carrying the
CYP2E1*2 allele in comparison to subjects homozygous for the
CYP2E1*1 allele under otherwise identical conditions.
The sensitivity for the detection of mutations by SSCP techniques using polyacrylamide gels in the absence or presence of glycerol has been found to be 90% and 70%, respectively (28). Some exons were run in the absence of glycerol, and additional bands were then obtained, but sequencing revealed no exon mutations.2 Statistically, we may have missed one additional mutation in one or two of the samples, although this would not change the conclusions drawn from the study.
Because no crystal structure of CYP2E1 or any other mammalian P450 is
available, alignments and homology-building models are used to make
predictions concerning the localization of amino acids in the
three-dimensional structure of the enzyme. None of the amino acid
substitutions are located in the substrate recognition sites predicted
by Gotoh (29) and are thus not expected to be directly involved in
substrate binding. Hasemann et al. (30) made a structural
alignment of three bacterial P450 structures and used this to align
some of the mammalian P450 on the amino acid level. Using this model,
it is apparent that both amino acid exchanges are located in the
1-sheet, which implies that they are closely related in space.
However, until detailed models or crystal structures are available, the
precise role of these residues will remain unknown. Interestingly,
Arg76 is conserved in all species investigated thus far
[namely, human (31), macaque (32), rat (31), mouse (33), rabbit (34), and hamster (35)], which indicates an important function for this
residue. This is in agreement with our data, which show altered expression of functional enzyme in the mutated variant.
Val389 is also well conserved, but in the macaque,
isoleucine has replaced valine, which is the same amino acid exchange
found in the CYP2E1*3 allele. In line with an assumption
that such an exchange would not affect the function of CYP2E1, our
expression data confirm the lack of functional importance of this amino
acid exchange.
Our sequence analysis indicates that the flanking regions of the human CYP2E1 gene are highly polymorphic. In specific areas, up to 5% of all bases were different between the DraI C allele and the wild-type allele (see Fig. 1). An increased rate of transcription of the CYP2E1 gene has been shown to occur in rats at high ethanol concentrations (36), although the primary level for regulation of CYP2E1 in this species by ethanol is at the post-translational level (37, 38). In a preliminary study, Lucas et al. (15) found that human subjects differ with respect to inducibility of the CYP2E1 enzyme by ethanol. The extent of inducibility was lower among subjects of the c2 and DraI C genotypes. In other studies, however, the c2 allele has been shown to be more effectively expressed than the c1 allele in transfected HepG2 cells (26). Nevertheless, accumulating data suggest the occurrence of two populations of humans that are of high and low CYP2E1 ethanol inducibility,3 and it is plausible that the cause of these differences can be found at some additional polymorphic sites in the flanking regions of the CYP2E1 gene, a hypothesis supported by the present finding of a high number of mutations in the DraI C allele. Further studies are needed to resolve this question.
It is interesting to note the high number of mutations in the flanking regions of the DraI C allele compared with the wild-type (DraI D) allele. By contrast, the almost complete absence of functional mutations in the open reading frame in both Caucasian and Asian populations indicates a selection for preservation of alleles encoding enzymes with the conserved amino acid sequence. Furthermore, the only functionally important mutation found did not abolish the activity of the enzyme, which further stresses the importance of the gene product. Thus, it is conceivable that CYP2E1 is of high physiological importance for humans. One might assume that a major factor in the past has been its ability to participate in the minor acetone-involving gluconeogenetic pathway (3) and that mutated CYP2E1 genes have not been beneficial for survival. However, no alteration in physiological function by homozygous inactivation of this gene was observed in well-fed mice (39). Because these mice have not been stressed dietarily, the caloric restriction selection theory for preservation of a functionally intact CYP2E1 gene in humans is not contradictory to the findings in the knock-out mice.
In conclusion, our data show that the open reading frame of the human CYP2E1 gene is surprisingly well conserved both in Asians and in Caucasians. This might suggest important endogenous functions and could indicate a pronounced endogenous role of this P450 in humans under certain conditions.
| |
Acknowledgments |
|---|
Dr. Ylva Terelius, being homozygous for the DraI C allele, is gratefully acknowledged.
| |
Footnotes |
|---|
Received July 15, 1996; Accepted December 5, 1996
1 A new nomenclature system has recently been proposed for CYP2D6 alleles (40). This system is based on general recommendations for allele nomenclature, and the different alleles are denoted CYP2D6*n. Each allele is assigned a specific number. In accordance with this, we propose a similar system for designation of the CYP2E1 alleles with the following numbers: CYP2E1*1, wild-type sequence; CYP2E1*2, G1168A R76H; CYP2E1*3 G10059A V389I.
2 Y. Hu, unpublished observations.
3 I. Dupont, D. Lucas, P. Clot, M. Seccia, C. Menez, and E. Albano, submitted for publication.
This work was supported by grants from The Swedish Alcohol Research Fund and from The Swedish Medical Research Council.
Send reprint requests to: Magnus Ingelman-Sundberg, Ph.D., Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, S-171 77 Stockholm, Sweden. E-mail: maging{at}ki.se
| |
Abbreviations |
|---|
P450, cytochrome P450; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; SSCP, single-stranded conformation polymorphism.
| |
References |
|---|
|
|
|---|
| 1. |
Warner, M. and
J.-Å. Gustafsson.
Effect of ethanol on cytochrome P450 in the rat brain.
Proc. Natl. Acad. Sci. USA.
91:1019-1023 (1994) |
| 2. | Tindberg, N., H. A. Baldwin, A. J. Cross, and M. Ingelman-Sundberg. Induction of cytochrome P450 2E1 expression in rat and gerbil astrocytes by and inflammatory factors and ischemic injury. Mol. Pharmacol. 50:1065-1072 (1996)[Abstract]. |
| 3. | Ronis, M. J. J., K. O. Lindros, and M. Ingelman-Sundberg. The cytochrome P4502E subfamily, in Cytochromes P450, Pharmacological and Toxicological Aspects (I. Ioannides, ed.). CRC Press, Boca Raton, FL, 211-239. |
| 4. | Terelius, Y., K. O. Lindros, E. Albano, and M. Ingelman-Sundberg. Isozyme-specificity of cytochrome P450-mediated hepatotoxicity, in Frontiers Biotransformation (H. Rein and K. Ruckpaul, eds.). Vol. 8. Akademie Verlag, Berlin, 186-231 (1993). |
| 5. | Ingelman-Sundberg, M., I. Johansson, H. Yin, Y. Terelius, E. Eliasson, P. Clot, and E. Albano. Ethanol-inducible cytochrome P4502E1: genetic polymorphism, regulation, and possible role in the etiology of alcohol-induced liver disease. Alcohol 10:447-452 (1993)[Medline]. |
| 6. | Parkinson, A. An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol. Pathol. 24:45-57 (1996). |
| 7. | Ingelman-Sundberg, M. and I. Johansson. The molecular genetics of the human drug metabolizing cytochrome P450s, in Advances in Drug Metabolism in Man (G. Pacifici and G. N. Fracchia, eds.). Office for Official Publications of the European Communities, Luxembourg, 543-586 (1995). |
| 8. | Ekström, G., C. von Bahr, and M. Ingelman-Sundberg. Human liver microsomal cytochrome P-450 IIE1. Immunological evaluation of its contribution to microsomal ethanol oxidation, carbon tetrachloride reduction and NADPH oxidase activity. Biochem. Pharmacol. 38:689-693 (1989)[Medline]. |
| 9. | Wrighton, S. A., P. E. Thomas, D. T. Molowa, M. Haniu, J. E. Shively, S. L. Maines, P. B. Watkins, G. Parker, G. Mendez-Picon, W. Levin, and P. S. Guzelian. Characterisation of ethanol-inducible human liver N-nitrosodimethylamine demethylase. Biochemistry 25:6732-6735 (1986). |
| 10. | Rannug, A., A. K. Alexandrie, I. Persson, and M. Ingelman-Sundberg. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance. J. Occup. Environ. Med. 37:25-36 (1995)[Medline]. |
| 11. | Nedelcheva, V., I. Persson, I. Johansson, and M. Ingelman-Sundberg. Genetic polymorphism of human cytochrome P450 2E1. Methods Enzymol. 272:218-225 (1996)[Medline]. |
| 12. |
Iwahashi, K. K.,
H. Nakamura,
Y. Suwaki,
Y. Matsuo, and
Y. Ichikawa.
Relationship between genetic polymorphism of CYP2E1 and ALDH2, and possible susceptibility to alcoholism.
Alcohol Alcohol.
29:639-642 (1994) |
| 13. | Yu, M. W., A. Gladek-Yarborough, S. Chiamprasert, R. M. Santella, Y. F. Liaw, and C. J. Chen. Cytochrome P450 2E1, and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology 109:1266-1273 (1995)[Medline]. |
| 14. | Kato, S., M. Onda, N. Matsukura, A. Tokunaga, T. Tajiri, D. Y. Kim, H. Tsuruta, N. Matsuda, K. Yamashita, and P. G. Shields. Cytochrome P4502E1 (CYP2E1) genetic polymorphism in a case-control study of gastric cancer and liver disease. Pharmacogenetics 5:S141-S144 (1995). |
| 15. | Lucas, D., C. Menez, C. Girre, F. Berthou, P. Bodenez, I. Joannet, E. Hispard, L.-G. Bardou, and J.-F. Menez. Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics 5:298-304 (1995)[Medline]. |
| 16. | Kim, R. B. and D. O'Shea. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin. Pharmacol. Ther. 57:645-655 (1995)[Medline]. |
| 17. |
Johansson, I.,
E. Lundqvist,
L. Bertilsson,
M. L. Dahl,
F. Sjöqvist, and
M. Ingelman-Sundberg.
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
Proc. Natl. Acad. Sci. USA
90:11825-11829 (1993) |
| 18. | Johansson, I., M. Oscarson, Q. Y. Yue, L. Bertilsson, F. Sjöqvist, and M. Ingelman-Sundberg. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 46:452-459 (1994)[Abstract]. |
| 19. | Clot, P., E. Albano, E. Eliasson, M. Tabone, S. Arincò, Y. Israel, C. Moncada, and M. Ingelman-Sundberg. Cytochrome P4502E1 (CYP2E1) hydroxyethyl radical adducts as the major antigenic determinants for autoantibody formation among alcoholics. Gastroenterology 111:206-216 (1996)[Medline]. |
| 20. | Gustafson, S., J. A. Proper, E. J. W. Bowie, and S. S. Sommer. Parameters affecting the yield of DNA from human blood. Anal. Biochem. 165:294-299 (1987)[Medline]. |
| 21. | Persson, I., I. Johansson, H. Bergling, M.-L. Dahl, J. Seidegård, R. Rylander, A. Rannug, J. Högberg, and M. Ingelman-Sundberg. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett. 319:207-211 (1993)[Medline]. |
| 22. |
Andersson, S.,
D. N. Davis,
H. Dahlback,
H. Jörnvall, and
D. W. Russell.
Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme.
J. Biol. Chem.
264:8222-8229 (1989) |
| 23. |
Hu, Y.,
V. Mishin,
I. Johansson,
C. von Bahr,
A. Cross,
M. J. Ronis,
T. M. Badger, and
M. Ingelman-Sundberg.
Chlormethiazole as an efficient inhibitor of cytochrome P450 2E1 expression in rat liver.
J. Pharmacol. Exp. Ther.
269:1286-1291 (1994) |
| 24. | Johansson, I., G. Ekström, B. Scholte, D. Puzycki, H. Jörnvall, and M. Ingelman-Sundberg. Ethanol-, fasting-, and acetone-inducible cytochromes P-450 in rat liver: regulation and characteristics of enzymes belonging to the IIB and IIE gene subfamilies. Biochemistry 27:1925-1934 (1988)[Medline]. |
| 25. | Ingelman-Sundberg, M. and H. Glaumann. Incorporation of purified components of the rabbit liver microsomal hydroxylase system into phospholipid vesicles. Biochim. Biophys. Acta 599:417-35 (1980)[Medline]. |
| 26. |
Hayashi, S.,
J. Watanabe, and
K. J. Kawajiri.
Genetic polymorphisms in the 5 -flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene.
J. Biochem.
110:559-564 (1991) |
| 27. | Umeno, M., O. W. McBride, C. S. Yang, H. V. Gelboin, and F. J. Gonzalez. Human ethanol-inducible P450IIE1: complete gene sequence, promoter characterization, chromosome mapping, and cDNA directed expression. Biochemistry 27:9006-9013 (1988)[Medline]. |
| 28. | Vidal-Puig, A. and D. E. Moller. Comparative sensitivity of alternative single-strand conformation polymorphism (SSCP) methods. Biotechniques 17:490-492 (1994)[Medline]. |
| 29. |
Gotoh, O.
Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences.
J. Biol. Chem.
267:83-90 (1992) |
| 30. | Hasemann, C. A., R. G. Kurumbail, S. S. Boddupalli, J. A. Peterson, and J. Deisenhofer. Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure 3:41-62 (1995)[Medline]. |
| 31. |
Song, B. J.,
H. V. Gelboin,
S. S. Park,
C. S. Yang, and
F. J. Gonzalez.
Complementary DNA and protein sequences of ethanol-inducible rat and human cytochrome P-450s. Transcriptional and post-transcriptional regulation of the rat.
J. Biol. Chem.
261:16689-16697 (1996) |
| 32. | Komori, M., O. Kikuchi, T. Sakuma, J. Funaki, M. Kitada, and T. Kamataki. Molecular cloning of monkey liver cytochrome P-450 cDNAs: similarity of the primary sequences to human cytochromes P-450. Biochim. Biophys. Acta 1171:141-146 (1992)[Medline]. |
| 33. | Freeman, J. E., D. Stirling, A. L. Russell, and C. R. Wolf. cDNA sequence, deduced amino acid sequence, predicted gene structure and chemical regulation of mouse cyp2e1. Biochem J. 281:689-695 (1992). |
| 34. |
Khani, S. C.,
T. D. Porter,
S. Fujita, and
M. J. Coon.
Organization and differential expression of two highly similar genes in the rabbit alcohol-inducible cytochrome P-450 subfamily.
J. Biol. Chem.
263:7170-7175 (1988) |
| 35. | Sakuma, T., M. Takai, T. Yokoi, and T. Kamataki. Molecular cloning and sequence analysis of hamster CYP2E1. Biochim. Biophys. Acta 1217:229-231 (1994)[Medline]. |
| 36. | Badger, T. M., J. Huang, M. Ronis, and C. K. Lumpkin. Induction of cytochrome P450 2E1 during chronic ethanol exposure occurs via transcription of the CYP2E1 gene when blood alcohol concentrations are high. Biochem. Biophys. Res. Commun. 190:780-785 (1993)[Medline]. |
| 37. |
Eliasson, E.,
I. Johansson, and
M. Ingelman-Sundberg.
Substrate-, hormone-, and cAMP regulated cytochrome P450 degradation.
Proc. Natl. Acad. Sci. USA
87:3225-3229 (1990) |
| 38. |
Roberts, B. J.,
B. J. Song,
Y. Soh,
S. S. Park, and
S. E. Shoaf.
Ethanol induces CYP2E1 by protein stabilization. Role of ubiquitin conjugation in the rapid degradation of CYP2E1.
J. Biol. Chem.
270:29632-29635 (1995) |
| 39. |
Lee, S. S. T.,
J. T. M. Buters,
T. Pineau,
P. Fernandez-Salguero, and
F. J. Gonzalez.
Role of cyp2e1 in the hepatotoxicity of acetaminophen.
J. Biol. Chem.
271:12063-12067 (1996) |
| 40. | Daly, A. K., J. Brockmöller, F. Broly, M. Eichelbaum, W. E. Evans, F. J. Gonzalez, J.-D. Huang, J. R. Idle, M. Ingelman-Sundberg, T. Ishizaki, E. Jacqz-Aigrain, U. A. Meyer, D. W. Nebert, V. M. Steen, C. R. Wolf, and U. M. Zanger. Nomenclature for human CYP2D6 alleles. Pharmacogenetics, in press. |
This article has been cited by other articles:
![]() |
Amal Al Omari and D. J. Murry Pharmacogenetics of the Cytochrome P450 Enzyme System: Review of Current Knowledge and Clinical Significance Journal of Pharmacy Practice, June 1, 2007; 20(3): 206 - 218. [Abstract] [PDF] |
||||
![]() |
J. Meletiadis, S. Chanock, and T. J. Walsh Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy Clin. Microbiol. Rev., October 1, 2006; 19(4): 763 - 787. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-Y. Park, K.-A. Kim, P.-W. Park, and J.-M. Ha Effect of High-Dose Aspirin on CYP2E1 Activity in Healthy Subjects Measured Using Chlorzoxazone as a Probe J. Clin. Pharmacol., January 1, 2006; 46(1): 109 - 114. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Guo, Y. Zhang, Y. Wang, X. Chen, D. Si, D. Zhong, J. P. Fawcett, and H. Zhou ROLE OF CYP2C9 AND ITS VARIANTS (CYP2C9*3 AND CYP2C9*13) IN THE METABOLISM OF LORNOXICAM IN HUMANS Drug Metab. Dispos., June 1, 2005; 33(6): 749 - 753. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Aldridge, J. A. Gibbons, M. M. Flaherty, M. L. Kreider, J. A. Romano, and E. D. Levin Heterogeneity of Toxicant Response: Sources of Human Variability Toxicol. Sci., November 1, 2003; 76(1): 3 - 20. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Glauser Advancing the Medical Management of Epilepsy: Disease Modification and Pharmacogenetics J Child Neurol, January 1, 2002; 17(1_suppl): S85 - S93. [Abstract] [PDF] |
||||
![]() |
D. G. McCarver ADH2 and CYP2E1 Genetic Polymorphisms: Risk Factors for Alcohol-Related Birth Defects Drug Metab. Dispos., April 1, 2001; 29(4): 562 - 565. [Abstract] [Full Text] |
||||
![]() |
M. Ingelman-Sundberg Implications of Polymorphic Cytochrome P450-Dependent Drug Metabolism for Drug Development Drug Metab. Dispos., April 1, 2001; 29(4): 570 - 573. [Abstract] [Full Text] |
||||
![]() |
S. M. Lankford, S. A. Bai, and J. A. Goldstein Cloning of Canine Cytochrome P450 2E1 cDNA: Identification and Characterization of Two Variant Alleles Drug Metab. Dispos., August 1, 2000; 28(8): 981 - 986. [Abstract] [Full Text] |
||||
![]() |
W. Tan, N. Song, G.-Q. Wang, Q. Liu, H.-J. Tang, F. F. Kadlubar, and D.-X. Lin Impact of Genetic Polymorphisms in Cytochrome P450 2E1 and Glutathione S-Transferases M1, T1, and P1 on Susceptibility to Esophageal Cancer among High-Risk Individuals in China Cancer Epidemiol. Biomarkers Prev., June 1, 2000; 9(6): 551 - 556. [Abstract] [Full Text] |
||||
![]() |
T. E. Jackson, P. D. Lilly, L. Recio, P. M. Schlosser, and M. A. Medinsky Inhibition of Cytochrome P450 2E1 Decreases, but Does Not Eliminate, Genotoxicity Mediated by 1,3-Butadiene Toxicol. Sci., June 1, 2000; 55(2): 266 - 273. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||